Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19. SIGNIFICANCE: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies.

Authors

Institutions

Publication Details

Journal
UNC Libraries
Published
2025-04-18
DOI
https://doi.org/10.17615/654a-sj66
Primary Topic
COVID-19 and healthcare impacts
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes

Gayathri Nagaraj, Chris Labaki, Ryan C. Lynch, Anup Kasi et al.
UNC Libraries
COVID-19 and healthcare impacts
article

Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes

Gayathri Nagaraj, Chris Labaki, Ryan C. Lynch, Anup Kasi, R. Alejandro Sica, Shilpa Gupta, Devendra Kc, Tahir Latif, Taylor K. Nonato, Leyre Zubiri, Andrew J. Portuguese, Cecilia A. Castellano, Monika Joshi, Ziad Bakouny, Michael Thompson, Pedram Razavi, Vadim S. Koshkin, Joy Awosika, Chih–Yuan Hsu, Ruben A. Mesa, Nathalie A. Johnson, Aditi Shastri, Nicole M. Kuderer, Dimpy P. Shah, Alicia Beeghly‐Fadiel, Jeremy L. Warner, Clara Hwang, Jacob C. Cogan, Mehmet Asım Bilen, Elizabeth J. Klein, Catherine Stratton, Pallawi Torka, Matthias Weiß, Melissa Accordino, Adam J. Olszewski, Rana R. McKay, Sanjay Mishra, Trisha M. Wise‐Draper, Christopher Su, Daniel P. Mundt, Yu Shyr, Christopher R. Friese, Babar Bashir, Stephanie Berg, Amanda Nizam, Gary H. Lyman, Hyma Vani Polimera, Sarit Assouline, Matthew Puc, Daniel H. Kwon, Xuanyi Li, Rachel Rosovski, Shailesh Advani, Sumit Shah, Daniel Hausrath, Andrew Schmidt, Keith Stockerl‐Goldstein, Samuel M. Rubinstein, Eric Lau, Divaya Bhutani
article en

Abstract

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19. SIGNIFICANCE: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies.

UNC Libraries
University of North Carolina at Chapel Hill (US)
Openalex Percentile: Top 56%
COVID-19 and healthcare impacts
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.